Form 8-K

8-K — INTERNATIONAL FLAVORS & FRAGRANCES INC

Accession: 0000051253-26-000032

Filed: 2026-08-04

Period: 2026-08-04

CIK: 0000051253

SIC: 2860 (INDUSTRIAL ORGANIC CHEMICALS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — iff-20260804.htm (Primary)

EX-99.1 (exhibit991foodingredientsd.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: iff-20260804.htm · Sequence: 1

iff-20260804

0000051253false00000512532026-08-042026-08-040000051253us-gaap:CommonStockMember2026-08-042026-08-040000051253iff:A1.800SeniorNotesDue2026Member2026-08-042026-08-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________________

FORM 8-K

_____________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) August 4, 2026

_____________________

INTERNATIONAL FLAVORS & FRAGRANCES INC.

(Exact Name of Registrant as Specified in Charter)

_____________________

New York 1-4858 13-1432060

(State or Other Jurisdiction

of Incorporation) (Commission

File Number) (I.R.S. Employer

Identification No.)

521 West 57th Street, New York, New York 10019

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code (212) 765-5500

___________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s)

Name of each exchange

on which registered

Common Stock, par value 12 1/2¢ per share IFF New York Stock Exchange

1.800% Senior Notes due 2026 IFF 26 New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

As announced on May 29, 2026, International Flavors & Fragrances Inc. (“IFF” or the “Company”) entered into a Purchase Agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners (“the Purchaser”), pursuant to which the Purchaser will purchase substantially all of the assets and assume and acquire certain of the rights and liabilities of IFF or its applicable affiliates that relate to or are used in connection with IFF’s Food Ingredients business (the “Food Ingredients disposal group”). As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership.

The Food Ingredients disposal group consists of a diversified portfolio across texturants, emulsifiers, plant-based solutions, and other specialty ingredients serving multinational food and beverage customers. The sale of the Food Ingredients disposal group is expected to close by the end of the second quarter of 2027, subject to applicable information and/or consultation requirements and customary closing conditions, including regulatory approvals, where required.

The Company determined that the sale of the Food Ingredients disposal group, combined with the sale of the Soy Crush, Concentrates, and Lecithin business, which was completed on March 2, 2026 (the “SCL disposal group”), represented a strategic shift that will have a major effect on IFF’s operations and results and met the held for sale and discontinued operations accounting criteria. Accordingly, for all periods presented, the results of these disposal groups are presented as discontinued operations under U.S. generally accepted accounting principles within this Form 8-K.

In order to assist investors in understanding the impact of the separation on the Company’s financial results, the Company is furnishing in Exhibit 99.1 to this Current Report, recast unaudited financial information for the three months ended March 31, 2025, three months ended June 30, 2025, three months ended September 30, 2025, three months and year ended December 31, 2025, and three months ended March 31, 2026 to reflect the separation of the Company’s Food Ingredients and SCL disposal groups and their classification as discontinued operations and certain other minor adjustments, primarily related to perimeter adjustments and allocation changes.

This Form 8-K and the accompanying Exhibit 99.1 do not restate any previously filed financial statements, nor do they reflect any subsequent events or adjustments, other than those necessary to reflect the reclassification of the Company’s Food Ingredients and SCL disposal groups as discontinued operations. This information should be read in conjunction with the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission.

The information contained in this Item 7.01 is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Cautionary Statement Under The Private Securities Litigation Reform Act of 1995

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management’s current assumptions, estimates, and expectations, including with respect to the Company’s financial and operational outlook (sales, adjusted operating EBITDA and cash flow), portfolio optimization initiatives (including the pending divestiture of our Food Ingredients disposal group), pricing, productivity and cost-discipline actions, capital allocation, future operations, growth potential, strategic investments and the expected effects of foreign exchange. These statements reflect management’s present views, are based on a series of expectations, assumptions, estimates and projections about the Company, are subject to change, and involve uncertainties that could cause actual results to differ materially.

Certain of such forward-looking information may be identified by such terms as “expect”, “anticipate”, “believe”, “intend”, “outlook”, “may”, “will”, “would”, “estimate”, “should”, “predict”, “plan”, “project”, “could”,

“potential”, “seek”, “target”, “continue”, “future”, and similar terms or variations thereof. These statements are not guarantees of future performance and are subject to risks and uncertainties that could lead to materially different outcomes.

Such risks, uncertainties and other factors include, among others, the following: (1) demand trends, competitive dynamics and customer concentration in the Company’s end markets; (2) execution of the Company’s strategic transformation and other strategic transactions, divestitures, acquisitions, collaborations and joint ventures; (3) working capital and inventory management; (4) outcomes of legal claims, disputes, regulatory investigations and litigation; (5) tariffs and trade actions, supply chain disruptions and macro events, including geopolitical developments, climate events, natural disasters, public health crises; (6) volatility in input costs (such as raw materials, transportation and energy); (7) attraction, retention and turnover of key employees and executives; (8) product innovation, time-to-market, product safety and quality; (9) cybersecurity incidents, artificial intelligence related risks, data privacy and compliance with data protection laws; (10) exposure to emerging markets, foreign currency fluctuations and international regulatory and political risks; (11) capital allocation, dividend policy and potential impairments of tangible or intangible assets; (12) the Company’s indebtedness, credit rating, liquidity, and access to capital; (13) pension and postretirement obligations; (14) compliance with federal, state, local and international rules and regulations, and regulatory, environmental, anti-corruption and sanctions laws and related ethical business practices; (15) protection and enforcement of intellectual property; (16) changes in tax laws and policies, tax audits and outcomes, including potential tax liabilities related to prior transactions; and (17) changes in federal, state, local and international rules and regulations.

The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. Important factors are described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in the Company’s subsequent filings with the SEC, and those disclosures are incorporated herein by reference.

The Company intends its forward-looking statements to speak only as of the time of such statements and does not undertake or plan to update or revise them as more information becomes available or to reflect changes in expectations, assumptions or results, whether as a result of new information, future events or otherwise. The Company can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Form 8-K or included in the Company’s other periodic reports filed with the SEC could materially and adversely impact the Company’s operations and the Company’s future financial results.

Any public statements or disclosures made by the Company following this communication that modify or impact any of the forward-looking statements contained in or accompanying this communication will be deemed to modify or supersede such outlook or other forward-looking statements in or accompanying this communication.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Number Description

99.1

International Flavors & Fragrances, Inc. Recast Unaudited Financial Information

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERNATIONAL FLAVORS & FRAGRANCES INC.

By: /s/ Michael DeVeau

Name: Michael DeVeau

Title: Executive Vice President, Chief Financial Officer

Dated: August 4, 2026

EX-99.1

Filename: exhibit991foodingredientsd.htm · Sequence: 2

Document

INTERNATIONAL FLAVORS & FRAGRANCES INC.

CONSOLIDATED STATEMENTS OF INCOME (LOSS) (UNAUDITED)(1)

Three months ended Three months ended Three months ended Three months ended Year ended Three months ended

March 31, June 30, September 30, December 31, December 31, March 31,

(DOLLARS AND SHARES IN MILLIONS EXCEPT PER SHARE AMOUNTS) 2025 2025 2025 2025 2025 2026

Net sales $ 2,050 $ 1,919 $ 1,869 $ 1,792 $ 7,630 $ 1,906

Cost of sales 1,198 1,095 1,070 1,064 4,427 1,077

Gross profit 852 824 799 728 3,203 829

Research and development expenses 155 170 162 162 649 154

Selling and administrative expenses 390 409 348 373 1,520 334

Amortization of acquisition-related intangibles 80 82 84 72 318 84

Impairment of goodwill 34 — — — 34 —

Restructuring and other charges 15 20 14 19 68 4

Losses (gains) on sale of assets — 1 — — 1 —

Operating profit (loss) 178 142 191 102 613 253

Interest expense 71 61 48 49 229 44

Gain on extinguishment of debt — (488) — — (488) —

Losses (gains) on business disposals — 111 — (2) 109 —

Other expense (income), net 19 20 13 21 73 13

Income (loss) before taxes from continuing operations 88 438 130 34 690 196

Provision (benefit) for income taxes 20 (112) 31 5 (56) 41

Net income (loss) from continuing operations 68 550 99 29 746 155

Net income (loss) from discontinued operations, net of tax (1,085) 49 (58) (11) (1,105) 15

Net income (loss) (1,017) 599 41 18 (359) 170

Net income attributable to non-controlling interests from continuing operations 1 — — — 1 1

Net income attributable to non-controlling interests from discontinued operations — — 1 — 1 —

Net income (loss) attributable to IFF shareholders $ (1,018) $ 599 $ 40 $ 18 $ (361) $ 169

Income (loss) per share - basic

Continuing operations $ 0.26 $ 2.15 $ 0.39 $ 0.11 $ 2.91 $ 0.60

Discontinued operations (4.24) 0.19 (0.23) (0.04) (4.32) 0.06

Net income (loss) per share - basic $ (3.98) $ 2.34 $ 0.16 $ 0.07 $ (1.41) $ 0.66

Income (loss) per share - diluted

Continuing operations $ 0.26 $ 2.14 $ 0.39 $ 0.11 $ 2.90 $ 0.60

Discontinued operations (4.22) 0.19 (0.23) (0.04) (4.31) 0.06

Net income (loss) per share - diluted $ (3.96) $ 2.33 $ 0.16 $ 0.07 $ (1.41) $ 0.66

Average number of shares outstanding

Average number of shares outstanding - basic 256 256 256 256 256 256

Average number of shares outstanding - diluted 257 257 257 257 257 257

INTERNATIONAL FLAVORS & FRAGRANCES INC.

RECAST REPORTABLE SEGMENT FINANCIAL INFORMATION (UNAUDITED)(1)

Three months ended

March 31, 2025 Three months ended

June 30, 2025 Three months ended

September 30, 2025 Three months ended

December 31, 2025 Year ended

December 31, 2025

(DOLLARS IN MILLIONS)

As Reported(3)

Recast

As Reported(3)

Recast

As Reported(3)

Recast

As Reported(3)

Recast

As Reported(3)

Recast

Taste

Sales $ 627 $ 650 $ 631 $ 654 $ 635 $ 658 $ 588 $ 611 $ 2,481 $ 2,573

Cost of sales (377) (394) (377) (397) (379) (399) (367) (387) (1,500) (1,577)

Gross profit 250 256 254 257 256 259 221 224 981 996

Research and development expenses (40) (41) (47) (49) (41) (41) (44) (45) (172) (176)

Selling and administrative expenses (94) (101) (98) (108) (103) (112) (101) (110) (396) (431)

Depreciation expense add-back(2)

15 15 16 17 16 17 18 19 65 68

Adjusted Operating EBITDA $ 131 $ 129 $ 125 $ 117 $ 128 $ 123 $ 94 $ 88 $ 478 $ 457

Scent

Sales $ 614 $ 614 $ 603 $ 603 $ 652 $ 652 $ 610 $ 610 $ 2,479 $ 2,479

Cost of sales (344) (343) (336) (336) (374) (372) (370) (370) (1,424) (1,421)

Gross profit 270 271 267 267 278 280 240 240 1,055 1,058

Research and development expenses (55) (58) (62) (62) (63) (64) (61) (62) (241) (246)

Selling and administrative expenses (86) (90) (92) (101) (97) (107) (91) (101) (366) (399)

Depreciation expense add-back(2)

15 15 17 17 17 18 18 19 67 69

Adjusted Operating EBITDA $ 144 $ 138 $ 130 $ 121 $ 135 $ 127 $ 106 $ 96 $ 515 $ 482

Health & Biosciences

Sales $ 540 $ 520 $ 577 $ 559 $ 577 $ 559 $ 589 $ 571 $ 2,283 $ 2,209

Cost of sales (298) (282) (311) (294) (315) (299) (322) (307) (1,246) (1,182)

Gross profit 242 238 266 265 262 260 267 264 1,037 1,027

Research and development expenses (52) (51) (55) (55) (57) (57) (55) (56) (219) (219)

Selling and administrative expenses (81) (92) (91) (101) (87) (101) (89) (99) (348) (393)

Depreciation expense add-back(2)

29 28 31 30 32 32 32 32 124 122

Adjusted Operating EBITDA $ 138 $ 123 $ 151 $ 139 $ 150 $ 134 $ 155 $ 141 $ 594 $ 537

Pharma Solutions

Sales $ 266 $ 266 $ 103 $ 103 — — — — $ 369 $ 369

Cost of sales (180) (180) (68) (68) — — — — (248) (248)

Gross profit 86 86 35 35 — — — — 121 121

Research and development expenses (5) (5) (3) (3) — — — — (8) (8)

Selling and administrative expenses (32) (32) (10) (10) — — — — (42) (42)

Depreciation expense add-back(2)

5 5 — — — — — — 5 5

Adjusted Operating EBITDA $ 54 $ 54 $ 22 $ 22 — — — — $ 76 $ 76

INTERNATIONAL FLAVORS & FRAGRANCES INC.

RECAST REPORTABLE SEGMENT FINANCIAL INFORMATION (UNAUDITED)(1)

Three months ended

March 31, 2026

(DOLLARS IN MILLIONS)

As Reported(3)

Recast

Taste

Sales $ 656 $ 680

Cost of sales (375) (393)

Gross profit 281 287

Research and development expenses (43) (45)

Selling and administrative expenses (101) (108)

Depreciation expense add-back(2)

16 18

Adjusted Operating EBITDA $ 153 $ 152

Scent

Sales $ 651 $ 651

Cost of sales (375) (375)

Gross profit 276 276

Research and development expenses (54) (56)

Selling and administrative expenses (92) (97)

Depreciation expense add-back(2)

18 18

Adjusted Operating EBITDA $ 148 $ 141

Health & Biosciences

Sales $ 595 $ 575

Cost of sales (327) (309)

Gross profit 268 266

Research and development expenses (55) (53)

Selling and administrative expenses (92) (105)

Depreciation expense add-back(2)

32 32

Adjusted Operating EBITDA $ 153 $ 140

_______________________

(1) Revised Consolidated Statements of Income (Loss) and Recast Reportable Segment Financial Information for all periods presented reflect the Food Ingredients and SCL disposal groups as discontinued operations.

(2) There is depreciation recorded within cost of sales, research & development expenses, and selling & administrative expenses, which is then added back to calculate segment Adjusted Operating EBITDA from continuing operations.

(3) As reported represents amounts as previously filed in our interim and annual financial statements prior to any impact of discontinued operations.

INTERNATIONAL FLAVORS & FRAGRANCES INC.

RECAST REPORTABLE SEGMENT FINANCIAL INFORMATION (UNAUDITED)(1)

Three months ended

March 31, 2025 Three months ended

June 30, 2025 Three months ended

September 30, 2025 Three months ended

December 31, 2025 Year ended

December 31, 2025

(DOLLARS IN MILLIONS)

As Reported(3)

Recast

As Reported(3)

Recast

As Reported(3)

Recast

As Reported(3)

Recast

As Reported(3)

Recast

Total Adjusted Operating EBITDA $ 578 $ 444 $ 552 $ 399 $ 519 $ 384 $ 437 $ 325 $ 2,086 $ 1,552

Reconciliation of Adjusted Operating EBITDA

Depreciation & Amortization (236) (142) (242) (146) (247) (151) (237) (142) (962) (581)

Interest Expense (71) (71) (61) (61) (48) (48) (49) (49) (229) (229)

Other Expense, net(a)

(20) (19) (10) (20) (14) (13) (21) (21) (65) (73)

Restructuring and Other Charges(b)

(17) (15) (21) (20) (16) (14) (16) (19) (70) (68)

Loss on Assets Classified as Held for Sale(c)

— — — — (108) — (7) — (115) —

Impairment of Goodwill(d)

(1,153) (34) — — — — — — (1,153) (34)

(Losses) Gains on Business Disposals(e)

— — (111) (111) — — 2 2 (109) (109)

Divestiture and Integration Costs(f)

(51) (51) (26) (26) (13) (11) (35) (10) (125) (98)

Strategic Initiative Costs(g)

(8) (8) (6) (6) (10) (10) (11) (11) (35) (35)

Regulatory Costs(h)

(11) (11) (53) (53) (7) (7) (35) (35) (106) (106)

Gain on Debt Extinguishment(i)

— — 488 488 — — — — 488 488

Entity Realignment Costs(j)

(1) (1) (4) (4) — — (3) (3) (8) (8)

Other(k)

(4) (4) (2) (2) — — (3) (3) (9) (9)

Income (Loss) Before Taxes $ (994) $ 88 $ 504 $ 438 $ 56 $ 130 $ 22 $ 34 $ (412) $ 690

Three months ended

March 31, 2026

(DOLLARS IN MILLIONS)

As Reported(3)

Recast

Total Adjusted Operating EBITDA $ 568 $ 433

Reconciliation of Adjusted Operating EBITDA

Depreciation & Amortization (246) (152)

Interest Expense (44) (44)

Other Expense, net(a)

(13) (13)

Restructuring and Other Charges(b)

(6) (4)

(Losses) Gains on Business Disposals(e)

(7) —

Divestiture and Integration Costs(f)

(24) (5)

Strategic Initiative Costs(g)

(9) (9)

Regulatory Costs(h)

(10) (10)

Entity Realignment Costs(j)

— (1)

Other(k)

— 1

Income (Loss) Before Taxes $ 209 $ 196

_______________________

a.2026 and 2025 as reported and recast figures primarily represents foreign exchange losses.

b.2026 and 2025 as reported and recast figures primarily represents costs related to the IFF Productivity Program including severance, fixed asset write-downs and site closure expenses, net of the gain on fixed assets previously written down.

c.As reported 2025 figures represents the loss on assets classified as held for sale of the Soy Crush, Concentrates and Lecithin (“SCL”) disposal group, which is reflected as discontinued operations.

d.As reported 2025 figures represents the impairment of goodwill related to the Food Ingredients reporting unit. Recast 2025 figures represents the impairment of goodwill attributable to the portion of the Food Ingredients reporting unit that is not included within the Food Ingredients or SCL disposal groups.

e.2025 as reported and recast figures primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business and sale of the Rene Laurent business in France.

f.2026 and 2025 as reported figures primarily represents costs related to the Company’s completed and anticipated divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. 2026 and 2025 recast figures exclude costs related to the planned divestiture of the Food Ingredients disposal group.

g.2026 and 2025 as reported and recast figures represents costs related to the Company’s strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services (GBS) Centers. In 2026, the GBS reorganization has been expanded to include additional functions such as customer service, supply chain and logistics in addition to human resources, accounting and finance, as well as additional efforts to automate processes and expand the use of artificial intelligence (AI) for these functions. These costs primarily consisted of external consulting fees and salaries of individuals who are fully dedicated to such efforts. Costs to develop software and AI are only included to the extent that they do not qualify for capitalization.

h.2026 and 2025 as reported and recast figures represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.

i.2025 as reported and recast figures represents the gain recognized on the extinguishment of debt in connection with the completion of the tender offers.

j.2025 as reported and recast figures represents costs related to a phased restructuring initiative aimed at optimizing its legal entity framework.

k.2025 as reported and recast figures represents the net impact of costs related to severance, including accelerated stock compensation expense, for certain executives who have separated from the Company, in addition to the impact of legislative changes in India related to the Wage Code.

Non-GAAP Financial Measures

This Exhibit 99.1 contains non-GAAP financial measures, including: (i) Adjusted Operating EBITDA.

Adjusted operating EBITDA excludes depreciation and amortization, interest expense, other expense (income), net, and certain non-recurring or unusual items such as restructuring and other charges, impairment of goodwill, losses (gains) on business disposals, loss on assets classified as held for sale, divestiture and integration costs, strategic initiatives costs, regulatory costs and other costs that are not related to recurring operations.

These non-GAAP financial measures are intended to provide additional information regarding our underlying operating results that reflect the sale of the Food Ingredients and SCL disposal groups and their classification as discontinued operations. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculation of such metrics.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover Page

Aug. 04, 2026

Entity Information [Line Items]

Document Type

8-K

Entity Registrant Name

INTERNATIONAL FLAVORS & FRAGRANCES INC

Entity Central Index Key

0000051253

Amendment Flag

false

Entity Incorporation, State or Country Code

Entity File Number

1-4858

Entity Tax Identification Number

13-1432060

Entity Address, Address Line One

521 West 57th Street,

Entity Address, City or Town

New York,

Entity Address, State or Province

Entity Address, Postal Zip Code

10019

City Area Code

(212)

Local Phone Number

765-5500

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock, par value 12 1/2¢ per share

Entity Information [Line Items]

Title of 12(b) Security

Common Stock, par value 12 1/2¢ per share

Trading Symbol

IFF

Security Exchange Name

NYSE

1.800% Senior Notes due 2026

Entity Information [Line Items]

Title of 12(b) Security

1.800% Senior Notes due 2026

Trading Symbol

IFF 26

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=iff_A1.800SeniorNotesDue2026Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: